A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/4045 (2006.01) A61K 31/165 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2617274
The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula(I), wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular, multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising an HDAC inhibitor and a compound effecting apoptosis of myeloma cells, preferably bortezomib, for simultaneous, separate or sequential use; to methods of treating myeloma; and to a pharmaceutical composition comprising said combination.
La présente invention concerne l'utilisation d'un inhibiteur HDAC, surtout un inhibiteur HDAC de formule (I), où les radicaux et symboles ont des significations telles que définies dans la spécification, pour la préparation d'un médicament pour le traitement du myélome, en particulier, des myélomes multiples, surtout le myélome résistant à la chimiothérapie conventionnelle ; une combinaison qui comprend un inhibiteur HDAC et un composé influençant l~apoptose des cellules du myélome, de préférence le bortezomib, pour une utilisation simultanée, séparée ou séquentielle; des méthodes de traitement du myélome; et une composition pharmaceutique qui comprend ladite combinaison.
Atadja Peter W.
Fetherstonhaugh & Co.
Novartis Ag
LandOfFree
Use of hdac inhibitors for the treatment of myeloma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hdac inhibitors for the treatment of myeloma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hdac inhibitors for the treatment of myeloma will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1920705